Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement

Logo poskytovatele

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

REDA Gianluigi CASSIN Ramona DOVRTĚLOVÁ Gabriela MATTEO Cristina GIANNOTTA Juri D'INCALCI Maurizio CORTELEZZI Agostino ZUCCHETTI Massimo

Rok publikování 2019
Druh Článek v odborném periodiku
Časopis / Zdroj Haematologica
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
Doi http://dx.doi.org/10.3324/haematol.2018.213157
Klíčová slova CNS involvement; Chronic Lymphocytic Leukemia; venetoclax
Popis Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.